Recent Conversations

  • RE: Expanded Access for Daraxonrasib / NCT07573215 - ceding to WCG or ...

    Jun 30, 2026 12:30 PM
    Posted in: IRB Forum

    Hi Kristi, While we are handling through our local IRB rather than WCG, I can ...

  • RE: IRB idiosyncrasies: Purview over group harms

    Jun 30, 2026 11:41 AM
    Posted in: IRB Forum

    I love the responses here! Thanks for starting the thread, David! My institution's ...

    1 person recommends this.

  • Expanded Access for Daraxonrasib / NCT07573215 - ceding to WCG or local ...

    Jun 30, 2026 11:24 AM
    Posted in: IRB Forum

    Hi everyone, For expanded access for Daraxonrasib / NCT07573215, are you ceding ...

  • RE: Departmental/College ancillary review

    Jun 30, 2026 11:22 AM
    Posted in: IRB Forum

    When you say "submission", do you mean submission to the campus IRB, or submission ...

  • RE: IRB idiosyncrasies: Purview over group harms

    Jun 30, 2026 11:14 AM
    Posted in: IRB Forum

    I think that this is a very interesting question and it's one that I have found ...

    1 person recommends this.

  • RE: How in depth are Exempt IRB Reviews for other universities

    Jun 30, 2026 11:11 AM
    Posted in: IRB Forum

    Our institution has a determination process that allows those who are unsure whether ...

Quick Links

Events and Dates